topSkip to main content

Menu, Secondary

Menu Trigger

Menu

New York's Leading Public Research Universities on the Forefront of Education and Innovation

New York’s leading public research universities are on the forefront of education and scientific innovation.


Only sixty-five years young, Stony Brook University is recognized as one of the nation’s top research universities, serving as a powerful engine for economic development, technological innovation and clinical care. SBU is not only transforming lives by revolutionizing cancer prognosis and advancing life-saving technologies for cardiac patients but also by offering a world-class education to students from all socio-economic backgrounds, providing them unmatched social and economic mobility.

The University at Buffalo was recognized as a research powerhouse back in 1989, when it became the first public university in New York invited to join the AAU, and its impact has only grown over the years. From developing new ways to treat memory loss in Alzheimer’s to pioneering minimally invasive surgical techniques, UB is making discoveries that lead to longer, healthier lives.

Learn more about the amazing work happening every day at New York's flagship public research universities:

An associate professor at Stony Brook University is leading a National Science Foundation (NSF)-funded research project focused on understanding how coastal flooding contributes to foundation damage.

 New study details how large-scale, cost-effective use of high-temperature superconducting wire is another step closer to reality

Our energy future may depend on high-temperature superconducting (HTS) wires.

At the heart of Buffalo’s rich history lies the Michigan Street Baptist Church, the city’s oldest continuously operating African American place of worship.. University at Buffalo archaeologists are uncovering the church’s past, one artifact at a time.
Hedge funds that invest in environmentally friendly stocks tend to outperform those that don’t, making it a smart strategy for both investors and hedge fund managers, according to new University at Buffalo School of Management research.
The first compound targeting Fatty Acid Binding Proteins (FABPs) for cancer-related pain & inflammation, developed through a Stony Brook research collaboration, has been cleared by the FDA for human trials.